Valuation: Intensity Therapeutics, Inc.

Market Cap 10.71M 9.65M 8.92M 8.06M 15.25M 1B 15.63M 107M 42.59M 538M 40.19M 39.34M 1.71B P/E 2026 *
-0.78x
P/E 2027 * -1.41x
Enterprise Value 10.71M 9.65M 8.92M 8.06M 15.25M 1B 15.63M 107M 42.59M 538M 40.19M 39.34M 1.71B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
96.28%
Yield 2026 *
-
Yield 2027 * -
1 day+6.15%
1 week-6.29%
Current month-3.53%
1 month-9.64%
3 months-21.90%
6 months-34.40%
Current year-68.02%
1 week 2.8
Extreme 2.8
3.39
1 month 2.8
Extreme 2.8
4.04
Current year 2.8
Extreme 2.8
11.07
1 year 2.8
Extreme 2.8
15
3 years 2.8
Extreme 2.8
286
5 years 2.8
Extreme 2.8
286
10 years 2.8
Extreme 2.8
286
Manager TitleAgeSince
Chief Executive Officer 67 2012-03-31
Director of Finance/CFO 57 2023-12-10
Corporate Officer/Principal - 2023-08-31
Director TitleAgeSince
Chairman 67 2012-03-31
Director/Board Member 60 2016-05-31
Director/Board Member 66 2018-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
7/16/26 Free

Controller/Auditor

11,000 0.4070%
7/16/26 Free

Chief Executive Officer

78,000 2.8859%
7/16/26 Free

Director

5,500 0.2035%
Change 5-day change 1-year change 3-year change Capi.($)
+6.15%-6.29%-66.36%-95.18% 10.71M
-1.06%-0.07%+60.76%+68.61% 67.53B
+1.60%+9.05%+14.32%+93.31% 60.74B
+0.54%-0.89%+20.16%+98.57% 55.66B
-0.95%+11.17%+22.21%+110.93% 47.97B
-0.23%+4.07%+25.63%+40.08% 45.24B
-6.40%-9.51%+181.99%+816.79% 39.08B
+1.97%+3.50%+25.78%+50.98% 35.34B
-0.91%-2.86%+79.65%+56.38% 33.45B
+1.05%+9.77%-37.66%+408.42% 26.49B
Average +0.18%+0.90%+32.65%+164.89% 41B
Weighted average by Cap. -0.45%+1.64%+43.76%+168.52%

Financials

2026 *2027 *
Net sales - -
Net income -12.49M -11.26M -10.4M -9.4M -17.79M -1.17B -18.23M -125M -49.68M -627M -46.87M -45.88M -2B -15.51M -13.98M -12.92M -11.68M -22.09M -1.45B -22.63M -155M -61.69M -779M -58.21M -56.97M -2.48B
Net Debt - -
Projected Income Statement - Annual - Intensity Therapeutics, Inc.
Logo Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. It is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.
Employees
-
Date Price Change Volume
26-11-11 US$3.280 +6.15% 6,707
26-11-10 US$3.090 -1.90% 8,653
26-11-09 US$3.150 +5.00% 56,659
26-11-06 US$3.000 -3.23% 15,443
26-11-05 US$3.100 -11.43% 50,211
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Intensity Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
3.280USD
Average target price
18.67USD
Spread / Average Target
+469.11%
  1. Stock Market
  2. Stocks
  3. INTS Stock